Connect with us

Industry

New medical cannabis flower products launch for UK patients

Curaleaf is bringing its second range of medical cannabis flower products to the UK market

Published

on

medical cannabis flower tolerance break
Curaleaf launched the first UK-manufactured cannabis flower product earlier this year. 

Curaleaf is bringing its second range of medical cannabis flower products to the UK market to improve access for patients.

Europe’s largest vertically integrated cannabis company Curaleaf, formally known as EMMAC Life Science Group, has launched its second range of medical cannabis flower products for the UK market, to help improve access and affordability for patients. 

The products are being manufactured in the UK and will be an addition to the company’s existing range of flower and oil products. 

The company launched the first UK-manufactured cannabis flower product earlier this year.

More affordable and accessible

The products are manufactured at Rokshaw Laboratories, Curaleaf’s leading UK Specials Manufacturer and the company’s second EU-GMP-certified laboratory.

Curaleaf’s business model which comprises cultivation, extraction, production and distribution, as well as bringing together pioneering science and research, has been designed to ensure high-quality medical cannabis flower is available, accessible and affordable for UK patients.

CEO of Curaleaf International, Antonio Costanzo, said: “We are very pleased to extend our range of medical cannabis products for the UK market. As a market leader, Curaleaf International is focused on solving the key patient and physician challenges relating to the price, accessibility, and sustainability of medical cannabis products.

“Our vertically integrated supply chain and GMP manufacturing facilities here in the UK allow us to scale rapidly to meet growing patient demand.”

Read more industry news at Cannabis Wealth

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister title and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email sarah@prohibitionpartners.com / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.